[Recent issue in the treatment of small-cell lung cancer].
Hiroshi Ueoka, Sakurao Hiraki
Abstract
Hiroshi Ueoka, Sakurao Hiraki
Abstract
Chemotherapy is currently a primary treatment modality for small-cell lung cancer (SCLC). However, in the limited stage, a combination of chemotherapy and thoracic irradiation (TI) was found to be superior to chemotherapy alone by meta-analysis. Recently, concurrent administration of cisplatin and etoposide with TI may be an optimal treatment. The usefulness of prophylactic cranial irradiation in complete responders was also confirmed by meta-analysis. Dose-intensive weekly chemotherapy failed to improve the treatment outcome in the extensive stage. Randomized trials to verify the effectiveness of high-dose chemotherapy with peripheral blood stem cell transplantation are in progress.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Chemotherapy is currently a primary treatment modality for small-cell lung cancer (SCLC). However, in the limited stage, a combination of chemotherapy and thoracic irradiation (TI) was found to be superior to chemotherapy alone by meta-analysis. Recently, concurrent administration of cisplatin and etoposide with TI may be an optimal treatment. The usefulness of prophylactic cranial irradiation in complete responders was also confirmed by meta-analysis. Dose-intensive weekly chemotherapy failed to improve the treatment outcome in the extensive stage. Randomized trials to verify the effectiveness of high-dose chemotherapy with peripheral blood stem cell transplantation are in progress.
Key concepts: Etoposide, Medicine, Prophylactic cranial irradiation, Chemotherapy, Oncology, Cisplatin, Lung cancer, Stage (stratigraphy)